EUVIMEDEUVIMED entdecken
Crossref

Liquid chromatography–tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study

Ganesan Padmini Tamilarasi, Krishnan Manikandan, Viswas Raja Solomon iD

Biomedical Chromatography · 2024

DOI: 10.1002/bmc.5825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Ganesan Padmini Tamilarasi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRMIST, Chennai, India. Hauptthemen laut MEDLINE: Bumetanide, Tandem Mass Spectrometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: SRM College of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Determining a drug's bioavailability and bioequivalence is important for developing and approving a drug product. The procedure supports applications for generic drug products and novel therapeutic substances, makes important decisions regarding safety and efficacy, and measures a drug's concentration in biological matrices. This study aimed to develop and validate a specific, simple, sensitive, and accurate method using liquid chromatography–tandem mass spectrometry (LC–MS) for measuring bumetanide (BUM) in human plasma. Chromatographic separation was achieved using a Hypurity C18 column (4.6 × 50 mm, 5 μm) under isocratic conditions, and LC–MS detected positive ionization acquisition modes. Protonated precursor to product ion transitions were observed at m/z 365.08 → 240.10 and 370.04 → 244.52 for BUM and internal standard, respectively. The linear range of BUM in plasma samples was 3.490–401.192 ng/mL. The inter‐precision value ranged from 1.76% to 4.75%. The inter‐accuracy value ranged from 96.46% to 99.95%. The method was adequately validated per the U.S. Food and Drug Administration guidelines, and the results were within permissible bounds. The C max and T max values were ~53.097 ± 13.537 ng/mL and 1.25 (0.67–5.00) h, respectively. The new approach showed satisfactory results for studying BUM in human plasma with potential use in pharmacokinetic and bioequivalence investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BumetanideTandem Mass SpectrometryHumansChromatography, LiquidBiological AvailabilityTherapeutic EquivalencyReproducibility of ResultsChromatography, High Pressure Liquid

Stichwörter der Autor:innen

LC-MS/MSbumetanideliquid-liquid extractionmethod developmentvalidation

Substanzen

Bumetanide

Autor:innen und Institutionen

  • Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRMIST, Chennai, India.
  • Department of Medicinal Chemistry, MNR College of Pharmacy, Sangareddy, India.

ORCID-Profile: Viswas Raja Solomon

Förderung

  • SRM College of Pharmacy

Zitieren

APA

Tamilarasi, G. P., Manikandan, K., & Solomon, V. R. (2024). Liquid chromatography–tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study. Biomedical Chromatography. https://doi.org/10.1002/bmc.5825

Vancouver

Tamilarasi GP, Manikandan K, Solomon VR. Liquid chromatography–tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study. Biomedical Chromatography. 2024. doi:10.1002/bmc.5825

BibTeX
@article{Tamilarasi2024,
  author = {Tamilarasi, Ganesan Padmini and Manikandan, Krishnan and Solomon, Viswas Raja},
  title = {Liquid chromatography–tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study},
  journal = {Biomedical Chromatography},
  year = {2024},
  doi = {10.1002/bmc.5825}
}
Kostenlos starten →